… Here we assess BCR-ABL mutations in the context of their impact on response after a …
mutation status may contribute to therapeutic decisions after imatinib failure or indeed after failure …

… We screened for mutations 171 patients failing imatinib … In our case, patients’ mutation status
changed after they … for mutations among 171 CML patients who failed imatinib therapy and …

… Dasatinib efficacy after imatinib failure by dosing schedule and baseline BCR-ABL mutation
status in patients with chronic myeloid leukemia in chronic phase (CML-CP). Haematologica …

… Moving from this background, we have collected and revised data obtained from the 76
patients who received dasatinib for resistance to IM and for whom mutational status prior to …

… detect BCR–ABL1 mutations in 202 CML patients with imatinib … We detected 68 mutations
in 58 imatinib-failure patients. … (A) By mutation status in all CP patients; (B) by onset of imatinib …

… ABL point mutations and/or amplification in patients who failed or lost response to imatinib
… The purpose of the present study was to evaluate the mutational status and clinical outcome …

… Mutational status and clinical outcome for each of the … ABL mutational screening, 21 we
analyzed 40 patients who showed up-front cytogenetic resistance to imatinib, defined as a failure …

… nilotinib in imatinib-resistant or -intolerant CML-CP patients (pts), we assessed the occurrence
of mutations and the efficacy stratified by BCR-ABL mutational status. Prior to therapy, 35 …

… mutations during imatinib therapy 13 and are associated with a poor response to nilotinib
and/or dasatinib therapy. Detecting these mutations at imatinib failure … and mutation status at …

… of BCR-ABL kinase domain mutations as a cause of imatinib resistance in CML and provide
evidence that knowledge of mutation status … unlikely to be the result of PCR-introduced error. …